North America Intravenous Immunoglobulin Market Forecast to 2028

Report Code : BMIRE00027592 | Region : North America | Industry : Pharmaceuticals | Published Date : 05/Dec/2022
North America Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)

The intravenous immunoglobulin market in North America is expected to grow from US$ 4,653.00 million in 2022 to US$ 7,272.33 by 2028. It is estimated to grow at a CAGR of 7.7% from 2022 to 2028.

Increasing Geriatric Population

As per the 2020 PROFILE OF OLDER AMERICANS report, in 2019, in the US, the population aged 65 and above was 54.1 million—30 million women and 24.1 million men. In 2019, 16% of the total population was aged 65 and above, which is expected to increase to 21.6% by 2040. Since 2009, the geriatric population in the US has increased by 14.4 million (or 36%). Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person’s body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve the use of IVIg. Thus, the increase in the geriatric population across the region is bolstering the growth of the intravenous immunoglobulin market.

Market Overview

The North America intravenous immunoglobulin market has been segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2021. Rising number of immunodeficiencies and autoimmune diseases, growing research & development activities on IVIg, and increasing demand for advanced therapies to treat diseases are among the prominent factors propelling the market growth in this region. The US accounts for a significant share of the intravenous immunoglobulin market in North America. The rising number of immunodeficiencies and autoimmune diseases in the US is likely to increase the demand for intravenous immunoglobulin. As per the National Institutes of Health, ~23.5 million Americans (over 7% of the population) suffer from an autoimmune disease, and the number is rising.

North America Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)

North America Intravenous Immunoglobulin Market Segmentation

The North America intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.

Based on application, the North America intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022. Based on distribution channel, the North America intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022. Based on end user, the North America intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022. Based on country, the market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.

ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.

● ADMA Biologics, Inc.

● Bio Products Laboratory Ltd.

● CSL Behring (CSL Limited)

● Grifols, S.A.

● Kedrion S.p.A

● Octapharma AG

● Pfizer Inc.

● Prothya Biosolutions B.V.

● Shanghai RAAS

● Takeda Pharmaceutical Company Limited

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Intravenous Immunoglobulin Market – By Type

1.3.2 North America Intravenous Immunoglobulin Market – By Application

1.3.3 North America Intravenous Immunoglobulin Market – By Distribution Channel

1.3.4 North America Intravenous Immunoglobulin Market – By End User

1.3.5 North America Intravenous Immunoglobulin Market – By Country

2. North America Intravenous Immunoglobulin Market– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Intravenous Immunoglobulin Market – Market Landscape

4.1 Overview

4.2 North America PEST Analysis

4.3 Expert Opinion

5. North America Intravenous Immunoglobulin Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Immunodeficiency Diseases

5.1.2 Increasing Geriatric Population

5.2 Market Restraints

5.2.1 Adverse Effects of Immunoglobulin Therapy

5.3 Market Opportunities

5.3.1 Growing Pharmaceutical Industry

5.4 Future Trends

5.4.1 Strong Pipeline Candidates for IVIG

5.5 Impact Analysis

6. Intravenous Immunoglobulin Market– North America Analysis

6.1 North America Intravenous Immunoglobulin Market Revenue Forecast and Analysis

7. North America Intravenous Immunoglobulin Market Revenue and Forecast to 2028– by Type

7.1 Overview

7.2 North America Intravenous Immunoglobulin Market, By Type 2022 & 2028 (%)

7.3 IgG

7.3.1 Overview

7.3.2 IgG Revenue and Forecast to 2028 (US$ Million)

7.4 IgM

7.4.1 Overview

7.4.2 IgM - Revenue and Forecast to 2028 (US$ Million)

7.5 IgA

7.5.1 Overview

7.5.2 IgA - Revenue and Forecast to 2028 (US$ Million)

7.6 IgE

7.6.1 Overview

7.6.2 IgE - Revenue and Forecast to 2028 (US$ Million)

7.7 IgD

7.7.1 Overview

7.7.2 IgD - Revenue and Forecast to 2028 (US$ Million)

8. North America Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Application

8.1 Overview

8.2 North America Intravenous Immunoglobulin Market, By Application 2022 & 2028 (%)

8.3 Hypogammaglobulinemia

8.3.1 Overview

8.3.2 Hypogammaglobulinemia - Market Revenue and Forecast to 2028 (US$ Million)

8.4 Chronic Inflammatory Demyelinating Polyneuropathy

8.4.1 Overview

8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy - Market Revenue and Forecast to 2028 (US$ Million)

8.5 Immunodeficiency Diseases

8.5.1 Overview

8.5.2 Immunodeficiency Diseases - Market Revenue and Forecast to 2028 (US$ Million)

8.6 Myasthenia Gravis

8.6.1 Overview

8.6.2 Myasthenia Gravis - Market Revenue and Forecast to 2028 (US$ Million)

8.7 Multifocal Motor Neuropathy

8.7.1 Overview

8.7.2 Multifocal Motor Neuropathy - Market Revenue and Forecast to 2028 (US$ Million)

8.8 Idiopathic Thrombocytopenic Purpura

8.8.1 Overview

8.8.2 Idiopathic Thrombocytopenic Purpura - Market Revenue and Forecast to 2028 (US$ Million)

8.9 Inflammatory Myopathies

8.9.1 Overview

8.9.2 Inflammatory Myopathies - Market Revenue and Forecast to 2028 (US$ Million)

8.10 Specific Antibody Deficiency

8.10.1 Overview

8.10.2 Specific Antibody Deficiency - Market Revenue and Forecast to 2028 (US$ Million)

8.11 Guillain-Barre Syndrome

8.11.1 Overview

8.11.2 Guillain-Barre Syndrome - Market Revenue and Forecast to 2028 (US$ Million)

8.12 Others

8.12.1 Overview

8.12.2 Others - Market Revenue and Forecast to 2028 (US$ Million)

9. North America Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Distribution Channel

9.1 Overview

9.2 North America Intravenous Immunoglobulin Market, By Distribution Channel 2022 & 2028 (%)

9.3 Hospital Pharmacy

9.3.1 Overview

9.3.2 Hospital Pharmacy - Market Revenue and Forecast to 2028 (US$ Million)

9.4 Retail Pharmacy

9.4.1 Overview

9.4.2 Retail Pharmacy - Market Revenue and Forecast to 2028 (US$ Million)

9.5 Others

9.5.1 Overview

9.5.2 Others - Market Revenue and Forecast to 2028 (US$ Million)

10. North America Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by End User

10.1 Overview

10.2 North America Intravenous Immunoglobulin Market, By End User 2022 & 2028 (%)

10.3 Hospitals

10.3.1 Overview

10.3.2 Hospitals - Market Revenue And Forecasts To 2028 (US$ Million)

10.4 Specialty Clinics

10.4.1 Overview

10.4.2 Specialty Clinics - Market Revenue And Forecasts To 2028 (US$ Million)

10.5 Others

10.5.1 Overview

10.5.2 Others - Market Revenue And Forecasts To 2028 (US$ Million)

11. North America Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 – Country Analysis

11.1 Overview

11.1.1.1 US: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.1 Overview

11.1.1.1.2 US: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.3 US: Intravenous Immunoglobulin Market, by Type, 2019–2028 (US$ Million)

11.1.1.1.4 US: Intravenous Immunoglobulin Market, by Application, 2019–2028 (US$ Million)

11.1.1.1.5 US: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (US$ Million)

11.1.1.1.6 US: Intravenous Immunoglobulin Market, by End User, 2019–2028 (US$ Million)

11.1.1.2 Canada: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.1 Overview

11.1.1.2.2 Canada: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.3 Canada: Intravenous Immunoglobulin Market, by Type, 2019–2028 (US$ Million)

11.1.1.2.4 Canada: Intravenous Immunoglobulin Market, by Application, 2019–2028 (US$ Million)

11.1.1.2.5 Canada: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (US$ Million)

11.1.1.2.6 Canada: Intravenous Immunoglobulin Market, by End User, 2019–2028 (US$ Million)

11.1.1.3 Mexico: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.1 Overview

11.1.1.3.2 Mexico: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.3 Mexico: Intravenous Immunoglobulin Market, by Type, 2019–2028 (US$ Million)

11.1.1.3.4 Mexico: Intravenous Immunoglobulin Market, by Application, 2019–2028 (US$ Million)

11.1.1.3.5 Mexico: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (US$ Million)

11.1.1.3.6 Mexico: Intravenous Immunoglobulin Market, by End User, 2019–2028 (US$ Million)

12. North America Intravenous Immunoglobulin Market–Industry Landscape

12.1 Overview

12.2 Inorganic Growth Strategies

12.2.1 Overview

12.3 Organic Growth Strategies

12.3.1 Overview

13. Company Profiles

13.1 Takeda Pharmaceutical Company Limited

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Grifols, S.A.

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Pfizer Inc.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 ADMA Biologics, Inc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Bio Products Laboratory Ltd.

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Shanghai RAAS

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 Octapharma AG

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Kedrion S.p.A

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 CSL Behring (CSL Limited)

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Prothya Biosolutions B.V.

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms in Intravenous Immunoglobulin Market

Table 1.             North America Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)

Table 2.             US Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 3.             US Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 4.             US Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 5.             US Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 6.             Canada Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 7.             Canada Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 8.             Canada Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 9.             Canada Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 10.          Mexico Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Mexico Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 12.          Mexico Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 13.          Mexico Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Recent Inorganic Growth Strategies in the Intravenous Immunoglobulin Market

Table 15.          Recent Organic Growth Strategies in the Intravenous Immunoglobulin Market

Table 16.          Glossary of Terms in Intravenous Immunoglobulin Market

● ADMA Biologics, Inc.

● Bio Products Laboratory Ltd.

● CSL Behring (CSL Limited)

● Grifols, S.A.

● Kedrion S.p.A

● Octapharma AG

● Pfizer Inc.

● Prothya Biosolutions B.V.

● Shanghai RAAS

● Takeda Pharmaceutical Company Limited

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America intravenous immunoglobulin market.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the North America intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the intravenous immunoglobulin market, as well as those hindering it

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(North America Intravenous Immunoglobulin Market Forecast to 2028)
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry